Stock market fluctuations | Bristol-Myers Squibb (BMY.US) rose 5% as the company continues research on Alzheimer's disease.

The Zhtng Finance app learned that on Wednesday, Bristol-Myers Squibb (BMY.US) rose by 5% to $50.67. In terms of news, Bristol-Myers Squibb announced on Wednesday that they will recruit more participants for a late-stage trial to evaluate the safety and efficacy of Cobenfy in treating dementia-related mental illness in Alzheimer's disease. The company stated that they made this decision after discovering some "unethical behavior" at a few trial sites related to clinical research execution, and the patient data from these sites will be excluded from the primary analysis.